drugset

drugset / Trial / NCT06261060

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

NCT06261060 ↗

Phase 2 Active not recruiting 6 enrolled M.D. Anderson Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.

Timeline

Start: 2024-06-20
Primary completion: 2028-06-11
Completion: 2028-06-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	—	Oral

Indications